Ellen James, PhD
Ellen James, PhD

Head of R&D

Ellen has 12 years’ experience in research, development and clinical project management. Following a PhD and post-doc at Imperial College London, she joined Trio Medicines in 2014, a pharmaceutical subsidiary of the Phase 1 CRO Hammersmith Medicines Research. There she was responsible for the development programmes of new chemical entities, as well as project managing several Phase 1 and 2 clinical studies.

During her career, Ellen has worked with regulatory agencies such as MHRA, EMA and FDA; managed teams of scientists; and managed subcontractors for CMC, nonclinical studies and clinical trials; she also has experience of the ICH guidelines and GxP environments. 

Ellen joined Small Pharma as Clinical Research Manager in 2017.

About Small Pharma

We’re a mental health drug development company that’s accelerating the development of fast acting antidepressant treatments using DMT based therapies. We’re dedicated to making a difference.

With a focus on innovative approaches and committed to challenging the status quo, we’re targeting the root causes of depression and hoping to unlock the minds of millions.

Get Small Pharma updates

    Investor Deck

    Follow us: